Press Releases

Back to list BIORCHESTRA Scientific Founder, Chairman, and Chief Executive Officer Joins the Republic of Korea (ROK) Official State Visit to the United States The...

Back to list BIORCHESTRA Announces Significant Progress in Studies of BMD-001 Drug Program Encouraging non-human primate (NHP) findings support the progression of IV-formulated BMD-001 ahead of formal...

Back to list BIORCHESTRA Expands Executive Leadership Team with the Appointment of David Oxley as Chief Business Officer CAMBRIDGE, Mass. and DAEJEON, South Korea, April 5, 2023 — BIORCHESTRA, a...

Back to list BIORCHESTRA Pens a Pact Worth up to $861M for Central Nervous System(CNS)-Targeted Polymeric Nanoparticle for Intravenous Delivery of Nucleic Acid Therapies CAMBRIDGE,...

Back to list BIORCHESTRA Participating in Two Upcoming Therapeutic RNA-Focused Events CAMBRIDGE, Mass. and DAEJEON, South Korea, March 8, 2023 /PRNewswire/ — BIORCHESTRA, a biotherapeutics company focused on the treatment of...

Back to list BIORCHESTRA receives Citation from the Korean Minister of Trade, Industry, and Energy A leader in creating jobs through the advancement of RNA-based...

Back to list BIORCHESTRA Announces that its Proprietary Compound, BMD-001, Reduces Amyloid-β and Tau Inflammatory Symptoms in Primate Models for Alzheimer’s Disease at the RNA...

Back to list BIORCHESTRA appointed Dr. Gabriel Helmlinger (Ph.D., DABT) as Head of Translational and Clinical Pharmacology, Toxicology BIORCHESTRA, headquartered in Daejeon, South Korea, appointed Dr. Gabriel...

Back to list BIORCHESTRA, presenting lead candidate BMD-001 for Alzheimer’s disease and drug delivery system technology at the 2022 BIO International Convention BIORCHESTRA Co., Ltd...

Back to list BIORCHESTRA Participated in Formulation and Delivery BIORCHESTRA is a leading RNA therapeutics company that develops novel RNA-based therapeutics and drug delivery systems...

Back to list BIORCHESTRA Announces 45 Million USD Series C Fundraising BIORCHESTRA is a leading RNA therapeutics company whose lead programs focus on neurodegenerative diseases...

Back to list BIORCHESTRA, SK Biopharmaceuticals collaborate to develop miRNA-targeted therapeutics BIORCHESTRA and SK Biopharmaceuticals announced today that they have forged a partnership to research...

Back to list BIORCHESTRA will present data on the therapeutic efficacy of their proprietary ASO against pathological miRNA, a key modulator of neuroinflammation and neurodegeneration,...

Back to list BIORCHESTRA appoints pharma veteran and Moderna and Akcea (Ionis) CMO “Dr. Louis St. L. O’Dea” as CMO of BIORCHESTRA BIORCHESTRA is a...

Back to list Biorchestra Named Awardee in NYC Innovation QuickFire Challenge on Neuroscience Johnson & Johnson Innovation announced today that Biorchestra has been selected as...

Back to list Biorchestra “Discussing the Material Transfer Agreement (MTA) with Big Pharma for Alzheimer’s treatment” Biorchestra announced on the 25th that it has received...

Back to list Chong Kun Dang invests ￦5 billion in Biorchestra Chong Kun Dang Holdings said that would invest 5 billion won ($4.1 million) in...